Eczema drug upadacitinib under Real-World safety check in china

NCT ID NCT05959083

Completed Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how safe and effective upadacitinib is for Chinese adolescents and adults with moderate to severe atopic dermatitis (eczema). About 200 participants will take the drug as prescribed by their doctor and be followed for up to 24 months. The goal is to track serious infections and other side effects in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: upadacitinib
What this could lead to: If successful, this could confirm that upadacitinib is a safe and effective option for managing moderate to severe atopic dermatitis in Chinese patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only includes Chinese patients, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

Contacts and locations

Locations

Chengdu Second Municipal People's Hospital /ID# 257732

Chengdu, Sichuan, 610017, China
Dermatology Hospital of Southern Medical University /ID# 261862

Guangzhou, Guangdong, 510091, China
First Affiliated Hospital of China Medical University /ID# 257641

Shenyang, Liaoning, 110001, China
Hangzhou First People's Hospital /ID# 261867

Hangzhou, Zhejiang, 310003, China
Huashan Hospital, Fudan University /ID# 256456

Shanghai, Shanghai Municipality, 200040, China
Ningbo First Hospital /ID# 263884

Ningbo, Zhejiang, 315010, China
Peking University Third Hospital /ID# 257722

Beijing, Beijing Municipality, 100191, China
People's Hospital of Henan Province /ID# 257736

Zhengzhou, Henan, 450003, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 257726

Shanghai, Shanghai Municipality, 200065, China
Second Affiliated Hospital of Xian Jiaotong University /ID# 257733

Xi'an, Shaanxi, 710004, China
Shandong Dermatological Hospital /ID# 257727

Jinan, Shandong, 250022, China
Shanghai Skin Disease Hospital /ID# 257719

Shanghai, Shanghai Municipality, 200443, China
Sichuan Provincial People's Hospital /ID# 263898

Chengdu, Sichuan, 610072, China
The Eighth Affiliated Hospital, Sun Yat-sen universtiy /ID# 257737

Shenzhen, Guangdong, 518033, China
The First Affiliated Hospital Of Fujian Medical University /ID# 257725

Fuzhou, Fujian, 350005, China
The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 257723

Hangzhou, Zhejiang, 310009, China
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 257724

Wuhan, Hubei, 430022, China
West China Hospital, Sichuan University /ID# 257720

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.